person · Reporting owner

von Maltzahn Geoffrey

Disclosed activity across 2 companies

Tapewire entity: 137686
SEC CIK: 0001768286

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kaleido Biosciences, Inc.KLDO · Entity 129745	Director	June 30, 2021	July 01, 2021
Sana Biotechnology, Inc.SANA · Entity 4870	Director	February 03, 2021	February 18, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kaleido Biosciences, Inc.

Report date June 30, 2021 · Filed July 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29	Direct	15,000	Reported balance After 2021-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000

Sana Biotechnology, Inc.

Report date February 03, 2021 · Filed February 18, 2021 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.00 · Expires 2031-02-02	Direct	23,591	Reported balance After 2021-02-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2021-02-03 · Grant · Acquired 23,591 · Balance 23,591 F1: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2: The stock option shall vest and become exercisable in full on February 3, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired.

F2: The stock option shall vest and become exercisable in full on February 3, 2022.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2021 Filed Jul 1, 2021 16:19 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.44	$0.00	Disclosure SEC source: 0001209191-21-044380 · doc4.xml · derivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-29 Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionSeries A-2 Convertible Preferred Stock · Derivative	366,122	$0.00	$0.00	Disclosure SEC source: 0000899243-21-005736 · doc4.xml · derivative · entry 4 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Geoffrey A. von Malzahn 2020 GRAT Disclosed balance after: 0 Underlying: Common Stock · 366,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionSeries A-2 Convertible Preferred Stock · Derivative	1,464,488	$0.00	$0.00	Disclosure SEC source: 0000899243-21-005736 · doc4.xml · derivative · entry 3 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,464,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionCommon Stock	366,122	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-005736 · doc4.xml · nonDerivative · entry 2 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Geoffrey A. von Malzahn 2020 GRAT Disclosed balance after: 366,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionCommon Stock	1,464,488	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-005736 · doc4.xml · nonDerivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,464,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. Read SEC document
February 03, 2021 Filed Feb 5, 2021 17:22 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $25.00	$0.00	Disclosure SEC source: 0000899243-21-005083 · doc4.xml · derivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document
February 03, 2021 Filed Feb 18, 2021 19:04 UTC Amendment	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Option (Right to Buy) · Derivative	23,591	$0.00 Strike: $25.00	$0.00	Disclosure SEC source: 0000899243-21-007199 · doc4a.xml · derivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,591 Underlying: Common Stock · 23,591 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document
June 30, 2020 Filed Jul 1, 2020 16:16 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.43	$0.00	Disclosure SEC source: 0001209191-20-039729 · doc4.xml · derivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-29 Read SEC document
March 04, 2019 Filed Mar 4, 2019 20:09 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	ConversionSeries A Preferred Stock · Derivative	684,932	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-005957 · doc4.xml · derivative · entry 2 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 342,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. Read SEC document
March 04, 2019 Filed Mar 4, 2019 20:09 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	ConversionCommon Stock	342,466	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-005957 · doc4.xml · nonDerivative · entry 1 von Maltzahn Geoffrey · CIK 0001768286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.